← 返回

植物来源天然产物在多发性骨髓瘤临床前研究中的机制与转化见解:当前证据

英文原题:Mechanistic and translational insights into plant-derived natural products in preclinical multiple myeloma research: Current evidence.

查看英文原题

Mechanistic and translational insights into plant-derived natural products in preclinical multiple myeloma research: Current evidence.

PubMed 2026/01/08(内容时间) Transl Oncol Q2 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

多发性骨髓瘤(MM)是一种血液系统恶性肿瘤,其特征为异常浆细胞克隆性增殖,具有显著异质性和治疗难治性。尽管蛋白酶体抑制剂(PI)、免疫调节药物(IMiD)、单克隆抗体(mAb)及CAR-T 细胞疗法已用于治疗,复发和耐药仍是亟待解决的主要挑战。近年来,植物来源天然产物因具有多靶点协同作用而日益受到关注,在诱导MM细胞凋亡、逆转耐药和调节免疫微环境方面显示独特潜力,成为转化医学研究的新兴重点。本结构化叙述性综述系统总结14种植物来源天然产物的抗骨髓瘤机制,包括植物单体化合物(黄芩素、青蒿素、姜黄素、雷公藤红素、藤黄酸、白藜芦醇、人参皂苷、淫羊藿苷、冬凌草甲素、白花丹素、芒柄花素)及标准化植物提取物(马钱子根提取物、蒲公英黄酮、白花蛇舌草多糖)。综述重点介绍其对信号通路、细胞周期和免疫调节的多靶点作用,并讨论其克服耐药、优化联合治疗策略的潜在转化价值。文献检索PubMed、Web of Science和中国知网(CNKI)数据库,涵盖截至2025年1月发表的研究。尽管植物来源天然产物在MM治疗中显示出有前景的多靶点调节机制,单体化合物生物利用度低及提取物缺乏标准化仍限制临床转化。未来研究应整合系统药理学和临床研究,阐明多组分协同网络并开发新型靶向制剂,加速植物化学物从实验室向临床应用转化。

展开英文摘要原文

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of abnormal plasma cells, with marked heterogeneity and therapeutic refractoriness. Despite the introduction of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), and chimeric antigen receptor T-cell (CAR-T) therapy, relapse and drug resistance remain major challenges that urgently need to be addressed. Plant-derived natural products have attracted increasing attention in recent years due to their multi-target synergistic effects, demonstrating unique potential in inducing MM cell apoptosis, reversing drug resistance, and modulating the immune microenvironment-making them a rising focus in translational medicine research. In this structured narrative review, we systematically summarize the anti-myeloma mechanisms of fourteen plant-derived natural products, including plant-derived monomeric compounds (baicalein, artemisinin, curcumin, celastrol, gambogic acid, resveratrol, ginsenosides, icariin, oridonin, plumbagin, formononetin) and standardized plant extracts (Strychnos nux-vomica root extract, dandelion flavonoids, Hedyotis diffusa polysaccharides).

This review highlights their multi-target regulatory effects on signaling pathways, cell cycle modulation, and immune regulation, and further discusses their potential translational value in overcoming drug resistance and optimizing combination treatment strategies. Literature was retrieved from PubMed, Web of Science, and CNKI databases, covering studies published up to January 2025.

Although plant-derived natural products exhibit promising multi-target regulatory mechanisms in MM therapy, their clinical translation remains limited by poor bioavailability of single compounds and the lack of standardized extracts. Future research should integrate systems pharmacology with clinical studies to elucidate multi-component synergistic networks and develop novel targeted formulations, thereby accelerating the efficient translation of phytochemicals from bench to bedside.

论文信息

作者
Li L、Xu J、Yu L、Shi J、Li C、Gu J、Wang Y、Cui S
第一作者单位
Shandong University of Traditional Chinese Medicine, Jinan, China.China
通讯作者单位
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: csytcm@126.com.China
文献类型
综述
期刊
Translational oncology2026 Feb
原文标识
PubMed 41512703 · DOI 10.1016/j.tranon.2026.102666